13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q3 2022. See the latest, Q2 2026 →
Reported value
$14.35B
−15% on the quarter before
Positions
250
11 new · 115 sold out
Top 10
44.0%
of the value
Est. gain
−$2.23B
on stocks held all quarter
Est. return
−14.5%
on those stocks since Q2 2022
Positions as of Sep 30, 2022, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2022. Striped tiles are options.
Largest buys
Since Q2 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Ginkgo Bioworks Holdings Inc~$123.1MAdded · 1.6% → 2.8%+39,460,799 shares
- UiPath~$107.0MAdded · 3.8% → 4.1%+8,488,829 shares
- Roku Inc~$100.0MAdded · 5.7% → 4.7%+1,773,302 shares
- Zoom~$96.8MAdded · 6.1% → 5.6%+1,315,322 shares
- Twilio~$86.7MAdded · 3.5% → 3.3%+1,254,195 shares
- Nvidia~$85.8MAdded · 0.7% → 1.2%+706,738 shares
- Exact Sciences Corp~$84.1MAdded · 4.4% → 4.0%+2,589,937 shares
- Unity Software Inc~$66.5MAdded · 2.2% → 2.5%+2,087,448 shares
- Verve Therapeutics Inc~$46.7MAdded · 0.2% → 0.8%+1,359,735 shares
- Roblox~$38.3MAdded · 1.3% → 2.1%+1,069,592 shares
Largest sells
Since Q2 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Signify Health Inc~$576.8MCut · 1.8% → 0.4%−19,786,600 shares
- Spotify Technology Sa~$107.3MCut · 1.4% → 0.5%−1,243,076 shares
- Crispr Therapeutics Ag~$97.4MCut · 3.3% → 3.8%−1,490,409 shares
- Stratasys Ltd~$95.1MCut · 1.0% → 0.2%−6,600,411 shares
- Coinbase~$79.6MCut · 4.1% → 3.5%−1,234,090 shares
- Tesla~$66.3MCut · 6.5% → 7.5%−250,102 shares
- Somalogic IncCALL~$62.0MSold out · 0.4% → 0.0%−10,333,075 underlying
- Vertex Pharmaceuticals Inc~$60.2MCut · 0.6% → 0.3%−208,077 shares
- 1life Healthcare Inc~$49.1MSold out · 0.3% → 0.0%−5,800,797 shares
- Ionis Pharmaceuticals Inc~$43.7MCut · 1.0% → 1.1%−988,190 shares
Holdings
As of Sep 30, 2022. Changes are in shares against Jun 30, 2022, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TeslaCommon Stock · shares −5.8% · price +4.9% | 7.5% | $1.08B | +$51.0M | ||||||||
| ZoomCommon Stock · shares +14% · price −31.5% | 5.6% | $801.5M | −$324.2M | ||||||||
| Roku IncCommon Stock · shares +17% · price −40.6% | 4.7% | $672.2M | −$390.6M | ||||||||
| UiPathCommon Stock · shares +23% · price −26.1% | 4.1% | $581.1M | −$167.7M | ||||||||
| Exact Sciences CorpCommon Stock · shares +17% · price −34.8% | 4.0% | $570.6M | −$259.3M | ||||||||
| Intellia Therapeutics IncCommon Stock · shares +1.5% · price +21.3% | 3.8% | $540.4M | +$93.4M | ||||||||
| Crispr Therapeutics AgCommon Stock · shares −15% · price +12.6% | 3.8% | $538.3M | +$60.1M | ||||||||
| Teladoc Health IncCommon Stock · shares +2.8% · price −25.6% | 3.7% | $528.8M | −$177.4M | ||||||||
| BlockCommon Stock · shares +0.6% · price −37.2% | 3.5% | $505.5M | −$297.1M | ||||||||
| CoinbaseCommon Stock · shares −14% · price −17.4% | 3.5% | $497.7M | −$105.0M | ||||||||
| TwilioCommon Stock · shares +23% · price −34.3% | 3.3% | $472.0M | −$200.8M | ||||||||
| Beam Therapeutics IncCommon Stock · shares −3.4% · price +35.4% | 2.8% | $404.5M | +$105.8M | ||||||||
| Ginkgo Bioworks Holdings IncCommon Stock · shares +45% · price +1.3% | 2.8% | $395.7M | +$3.5M | ||||||||
| Shopify IncCommon Stock · shares −0.2% · price −13.8% | 2.7% | $391.5M | −$62.8M | ||||||||
| Draftkings IncCommon Stock · shares −2.2% · price +11.7% | 2.6% | $374.1M | +$39.3M | ||||||||
| Unity Software IncCommon Stock · shares +23% · price −20.3% | 2.5% | $358.8M | −$74.4M | ||||||||
| RobinhoodCommon Stock · shares −1.9% · price +0.4% | 2.3% | $332.4M | +$1.3M | ||||||||
| RobloxCommon Stock · shares +14% · price +19.7% | 2.1% | $303.7M | +$43.7M | ||||||||
| Fate Therapeutics IncCommon Stock · shares +1.6% · price −3.0% | 1.8% | $261.2M | −$7.9M | ||||||||
| Pagerduty IncCommon Stock · shares −0.6% · price −6.4% | 1.7% | $249.7M | −$17.1M | ||||||||
| Twist Bioscience CorpCommon Stock · shares +6.5% · price +3.5% | 1.6% | $235.3M | +$7.5M | ||||||||
| NvidiaCommon Stock · shares +105% · price −35.0% | 1.2% | $167.8M | −$44.2M | ||||||||
| Pacific Biosciences Of CaliforCommon Stock · shares +2.3% · price +3.1% | 1.2% | $166.6M | +$4.9M | ||||||||
| Ionis Pharmaceuticals IncCommon Stock · shares −21% · price +21.1% | 1.1% | $164.2M | +$28.6M | ||||||||
| Veracyte IncCommon Stock · shares +2.5% · price −5.6% | 1.1% | $150.8M | −$8.7M | ||||||||
| Total · 250 positions | 100% | $14.35B | −$2.23B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2022 to Q3 2022: 224 stocks held throughout, down $2.23B (−14.5%).
- Beam Therapeutics Inc+$105.8M+35%
- Intellia Therapeutics Inc+$93.4M+21%
- Crispr Therapeutics Ag+$60.1M+13%
- Tesla3:1 split+$51.0M+5%
- Roblox+$43.7M+20%
- Twilio−$200.8M−34%
- Exact Sciences Corp−$259.3M−35%
- Block−$297.1M−37%
- Zoom−$324.2M−32%
- Roku Inc−$390.6M−41%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 5 splits read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |